The PennZone

  • Home
  • Business
  • Health
  • Construction
  • Real Estate
  • Technology
  • Non-profit
  • Travel
  • Education

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Scoop Social Co. Launches a New Era of Mobile Hospitality — One Truck, Two Experiences
  • Going Solo Life publishes new travel guide for 2026
  • Jet Set: The Ultimate Coachella Afterparty
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • Why We're Holding the Line on Pricing
  • Moravian Academy Announces New Full-Tuition Impact Scholarship for Upper School Students
  • AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • National Focus Turns to Global Conflict, Families of Veterans Lost to Suicide Call for Recognition

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • ATTAIN Profiles the Invisible Billionaire Who Started With $75 and Died the Richest Man in A
  • Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • IWS Press Publishes "Smart Money Shortcuts to Becoming Rich" by Tyler G. Hicks
  • JGCMGS Details Architecture to Safeguard Assets From Unauthorized Phishing Scams
  • 21 Days: The Malta Deadline That Could Redraw the Finnish Online Casino Map
  • JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
  • U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • New Report Reveals Surprising Trends in Ohio Airport Accidents
  • Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
  • WCC Kitchens and Cabinets Featured on Selling Houses Australia
  • Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
  • Shincheonji Marks 42nd Anniversary: From a Basement to a Denomination Growing by Tens of Thousands Annually
  • Imagen Golf Selected as Exclusive Golf Instruction Partner at The Birds Nest in New Hope, PA
  • Brain Drain Unlimited Foundation Achieves Candid Platinum Seal of Transparency
  • Jackets for Jobs Hosts Smart & Sexy® Day Detroit for Women's History Month
  • Tint Academy Training in Dallas Texas: Learn Window Tint & PPF Installation
  • $IBG accelerates toward transformative merger with BlockFuel as $6 million raise fuels dual-industry growth strategy: N A S D A Q: IBG
  • High-Growth Power Infrastructure Play Targets AI Boom: 1606 Corp. Executes Aggressive Texas Expansion Strategy: 1606 Corp. (Stock Symbol: CBDW) $CBDW
  • Accelerating the Transformation into a U.S. Nuclear Fuel Cycle Leader: Frontier Nuclear and Minerals Inc. (N A S D A Q: FNUC)
  • Ozz Metals Ltd Secures 1-Tonne Gold Offtake Agreement
  • Cultural Heritage Gallery Presents: Two Free Irish History Presentations Open to the Public
  • Jet Set: The Ultimate Coachella Afterparty

Popular on PennZone

  • The Legal AI Showdown: Westlaw, Lexis, ChatGPT… or EvenSteven?
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
  • $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS

Similar on PennZone

  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • $IBG accelerates toward transformative merger with BlockFuel as $6 million raise fuels dual-industry growth strategy: N A S D A Q: IBG
  • CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia
  • JL Tox Consulting Responds to New ISO 10993-1:2025 Biocompatibility Standard Release
  • HRC Fertility to Celebrate Grand Opening of New Beverly Hills Location During National Infertility Awareness Week
  • Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch
  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
  • Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
  • JKS Financial Marks Five-Year Partnership with University of Pittsburgh Basketball, United Way
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us